AR123532A1 - Vacuna contra coronavirus, cepas de levadura, métodos de detección, métodos de tratamiento y usos - Google Patents

Vacuna contra coronavirus, cepas de levadura, métodos de detección, métodos de tratamiento y usos

Info

Publication number
AR123532A1
AR123532A1 ARP210102579A ARP210102579A AR123532A1 AR 123532 A1 AR123532 A1 AR 123532A1 AR P210102579 A ARP210102579 A AR P210102579A AR P210102579 A ARP210102579 A AR P210102579A AR 123532 A1 AR123532 A1 AR 123532A1
Authority
AR
Argentina
Prior art keywords
coronavirus
domain
vaccine
amino acid
acid sequence
Prior art date
Application number
ARP210102579A
Other languages
English (en)
Inventor
Hidalgo Tommy Idrovo
Lorena Itati Ibaez
Natalia Brenda Fernandez
Javier Santos
Cecilia Dalessio
Alejandro Daniel Nadra
Florencia Pignataro
Original Assignee
Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet
Univ De Buenos Aires Uba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet, Univ De Buenos Aires Uba filed Critical Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet
Priority to ARP210102579A priority Critical patent/AR123532A1/es
Priority to PCT/US2022/043578 priority patent/WO2023043868A2/en
Priority to EP22870656.0A priority patent/EP4401769A2/en
Publication of AR123532A1 publication Critical patent/AR123532A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Vacuna y obtención de anticuerpos contra coronavirus, cepas de levadura, métodos de detección, métodos de tratamiento y usos. La vacuna contra un coronavirus que comprende el dominio RBD de la proteína espiga de coronavirus deglicosilado y adyuvantes, en donde el dominio RDB es producido en P. pastoris. Entre otras, la secuencia de aminoácidos del dominio RBD puede ser la secuencia SEQ ID Nº 1 o SEQ ID Nº 2, en donde la vacuna puede comprender además uno o varios adyuvantes. Reivindicación 10: Una cepa de levadura transformada, caracterizada porque expresa y libera al medio una proteína que comprende la secuencia de aminoácidos del dominio RBD de la proteína espiga de SARS-CoV-2 unida a una secuencia de aminoácidos de reconocimiento de Sortasa A unida a una etiqueta His6, en donde la expresión es estable. Reivindicación 13: Un método de detección de anticuerpos anti coronavirus, caracterizado porque comprende al menos las siguientes etapas: a. contactar el dominio RBD deglicosilado de la proteína espiga de un coronavirus con una cantidad de una muestra biológica, en donde el dominio RBD es producido en P. pastoris; y b. incubar y revelar.
ARP210102579A 2021-09-16 2021-09-16 Vacuna contra coronavirus, cepas de levadura, métodos de detección, métodos de tratamiento y usos AR123532A1 (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ARP210102579A AR123532A1 (es) 2021-09-16 2021-09-16 Vacuna contra coronavirus, cepas de levadura, métodos de detección, métodos de tratamiento y usos
PCT/US2022/043578 WO2023043868A2 (en) 2021-09-16 2022-09-15 Coronavirus vaccine, yeast strains, methods of detection, methods of treatment and uses thereof
EP22870656.0A EP4401769A2 (en) 2021-09-16 2022-09-15 Coronavirus vaccine, yeast strains, methods of detection, methods of treatment and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP210102579A AR123532A1 (es) 2021-09-16 2021-09-16 Vacuna contra coronavirus, cepas de levadura, métodos de detección, métodos de tratamiento y usos

Publications (1)

Publication Number Publication Date
AR123532A1 true AR123532A1 (es) 2022-12-14

Family

ID=84578120

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102579A AR123532A1 (es) 2021-09-16 2021-09-16 Vacuna contra coronavirus, cepas de levadura, métodos de detección, métodos de tratamiento y usos

Country Status (3)

Country Link
EP (1) EP4401769A2 (es)
AR (1) AR123532A1 (es)
WO (1) WO2023043868A2 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257852A1 (en) 2003-04-10 2006-11-16 Chiron Corporation Severe acute respiratory syndrome coronavirus
US7879799B2 (en) 2006-08-10 2011-02-01 Institute For Systems Biology Methods for characterizing glycoproteins and generating antibodies for same
WO2019126762A2 (en) * 2017-12-22 2019-06-27 The Broad Institute, Inc. Cas12a systems, methods, and compositions for targeted rna base editing
US11690907B2 (en) * 2018-06-12 2023-07-04 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
US20210206810A1 (en) * 2019-11-20 2021-07-08 Ingenza Ltd. Detection of Optimal Recombinants Using Fluorescent Protein Fusions
CN112300251B (zh) * 2020-02-24 2022-04-05 成都威斯克生物医药有限公司 抗SARS-CoV-2感染的蛋白及疫苗
US11376320B2 (en) * 2020-03-05 2022-07-05 Iowa State University Research Foundation, Inc. Immunogenic and vaccine compositions against SARS-CoV-2
RU2720614C9 (ru) * 2020-04-23 2021-02-09 федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации Иммунобиологическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты)
CN111920946B (zh) * 2020-08-07 2021-05-28 合肥诺为尔基因科技服务有限公司 环二核苷酸修饰铝纳米粒疫苗佐剂-传递系统及基于其的SARS-CoV-2亚单位疫苗

Also Published As

Publication number Publication date
WO2023043868A3 (en) 2023-10-12
EP4401769A2 (en) 2024-07-24
WO2023043868A2 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
Li et al. Protozoa: amebiasis
De Jonckheere What do we know by now about the genus Naegleria?
Bechah et al. Identification of rickettsial infections by using cutaneous swab specimens and PCR
Austin et al. Palaeontology in a molecular world: the search for authentic ancient DNA
Dąbrowska et al. The use of a one-step PCR method for the identification of Microsporum canis and Trichophyton mentagrophytes infection of pets
Sunarto et al. Characteristics of cyprinid herpesvirus 3 in different phases of infection: implications for disease transmission and control
CN102863524A (zh) 诊断细粒棘球蚴病的重组抗原蛋白、其制备方法和用途
Neal Enzymic proteolysis by Entamoeba histolytica; biochemical characteristics and relationship with invasiveness
AR123532A1 (es) Vacuna contra coronavirus, cepas de levadura, métodos de detección, métodos de tratamiento y usos
Tavanti et al. Differential expression of secretory aspartyl proteinase genes (SAP1-10) in oral Candida albicans isolates with distinct karyotypes
Cole et al. Detection of an RNA-dependent RNA polymerase in mitochondria from a mitovirus-infected isolate of the Dutch Elm disease fungus, Ophiostoma novo-ulmi
Lue et al. [38] RNA polymerase II transcription in vitro
Zafrida et al. Optimization of crude protease production from Bacillus thuringiensis HSFI-12 and thrombolytic activity its enzyme dialysate
Yamaji et al. A salivary cystatin, HlSC-1, from the ixodid tick Haemaphysalis longicornis play roles in the blood-feeding processes
CN105296479A (zh) 一种桑树青枯病鉴定的特异性引物及其应用
Li et al. Molecular investigation of piroplasma infection in white yaks (Bos grunniens) in Gansu province, China
Da’dara et al. How schistosomes alter the human serum proteome
AL-Hosary Loop-Mediated Isothermal Amplification (LAMP) Assay for Diagnosis of Bovine Babesiosis (Babesia bovis infection) in Egypt: LAMP assay for diagnosis of bovine babesiosis
Zollfrank et al. Fluorescence immunohistochemical detection of Armillaria and Heterobasidion in Norway spruce
Okeke et al. Reverse transcription-3′ rapid amplification of cDNA ends-nested PCR of ACT1 and SAP2 mRNA as a means of detecting viable Candida albicans in an in vitro cutaneous candidiasis model
Karthikeyan et al. Development and comparison of ELISA and PCR methods for the early detection of Ganoderma disease of coconut
Ralte et al. Detection of Toxoplasma gondii targeting the repetitive microsatellite sequence by PCR.
Blanco et al. Differential PbP27 expression in the yeast and mycelial forms of the Paracoccidioides brasiliensis species complex
Suwarsono et al. The Evaluations of Bleach as Decontaminant Solution to Promote The Positivity Rate of Mycobacterium Tuberculosis Culture for Sputum Specimen
Arroyo et al. β-Glucosidase production by non-Saccharomyces yeasts isolated from vineyard